ALK and non-small cell lung carcinoma: A phase III study (ASCEND-4) found that the PFS of patients with stage IV ALK-p NSCLC and PS 0–1 is longer with ceritinib monotherapy than with platinum combination therapy (HR 0.55, 95% CI: 0.42–0.73) [36].